Previous 10 | Next 10 |
Esperion (ESPR +11.5%) stock rose following its Q4 results which beat analysts' estimates. FY 2021 net product sales grew 208.89% Y/Y to ~$40.05M. U.S. The company said Net Product Revenue of NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) tablets incre...
Esperion Therapeutics press release (NASDAQ:ESPR): Q4 GAAP EPS of -$1.77 beats by $0.52. Revenue of $15.4M (+59.8% Y/Y) beats by $0.92M. As of December 31, 2021, cash, cash equivalents, restricted cash and investment securities available-for-sale totaled $309.3 million compared with $305.0 mi...
– Unprecedented CLEAR Outcomes Study Achieved 90% MACE Accumulation in February 2022 – – U.S. Net Product Revenue of NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets Grew 12% Seq...
Esperion Therapeutics (NASDAQ:ESPR) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, before market open. The consensus EPS Estimate is -$2.29 and the consensus Revenue Estimate is $14.48M (+50.2% Y/Y). Over the last 1 year, ESPR has beaten EPS estimates 50% of the time ...
ANN ARBOR, Mich., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Tuesday, February 22, 2022. Following the release, company management will h...
– Unprecedented CLEAR Outcomes Trial Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in 2H 2022; Achieved 85% MACE Accumulation in December – – Fourth-quarter 2021 U.S. Net Product Revenue Estimated Between $12.0 to $12.5 Milli...
ANN ARBOR, Mich., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming virtual J.P. Morgan 40 th Annual Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern...
Intercontinental Exchange will add 138 securities to the ICE Biotechnology index and delete 26 as part of the annual reconstitution, effective prior to market open on December 20. Notable additions: Aurinia Pharmaceuticals (NASDAQ:AUPH), Anavex Life Sciences (NASDAQ:AVXL), Sesen Bio...
An increasing focus on integrating advanced technologies into research efforts to generate viable drugs for treating various critical ailments, and growing demand for therapies from an aging population, should boost the biotech industry's growth. Given this backdrop, Wall Street analysts expe...
ANN ARBOR, Mich., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced the closing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and accompanying warrants...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...